JLE

Médecine thérapeutique / Pédiatrie

MENU

Auto-immune myasthenia in childhood: possible new therapeutic approaches? Volume 17, issue 3, Juillet-Août-Septembre 2014

Authors
Unité de neurologie pédiatrique, Hôpital Necker-Enfants malades, AP-HP, 149, rue de Sèvres, 75015 Paris, France
* Tirés à part

Auto-immune myasthenia is a potentially very severe condition in children, with a high risk of acute decompensation and chronic motor disability. Treatment of the disorder remains complex and requires trained practitioners. Treatment includes anti-cholinesterases, combined with corticosteroids with or without immunosuppressors for modern-to-severe forms A wide range of immunosuppression therapies are used, which significantly improve symptoms. Rituximab is one such potentially positive treatment.